BackDeep Medicine Acquisition - Tradeable Rights - Oct 2026 Overview
Deep Medicine Acquisition Corp - Tradeable Rights - Oct 2026

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 P/E Ratio

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 (DMAQR) has a P/E ratio of -0.01, below the sector sector average of 35.6.

Get informed when a big investor buys or sells

+ Follow

P/E Ratio

-0.01

P/E Ratio

-0.01

The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.

P/E Ratio (Comparison Companies)

Loading

P/E Ratio History

Loading

P/E Ratio Comparison

Loading

Deep Medicine Acquisition - Tradeable Rights - Oct 2026 (DMAQR) FAQ

The latest P/E ratio for DMAQR is -0.01. That is below the sector sector average of 35.6. Investors often review this figure alongside Deep Medicine Acquisition - Tradeable Rights - Oct 2026's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, DMAQR currently prints -0.01 for P/E ratio, while the sector average sits near 35.6. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Deep Medicine Acquisition - Tradeable Rights - Oct 2026's growth, margins, and balance sheet.

A P/E ratio of -0.01 for Deep Medicine Acquisition - Tradeable Rights - Oct 2026 is not 'good' or 'bad' on its own. Compare it with the peer average (35.6) and with DMAQR's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting DMAQR's P/E ratio (-0.01), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.